Home
CYTK
CYTK News

Latest Cytokinetics Incorporated (CYTK) News on May 9, 2025

MT Newswires

11 hours ago

B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating

Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

15 hours ago

Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Cytokinetics to Hold Annual Meeting of Stockholders

GlobeNewswire

a day ago

Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

Zacks

a day ago

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

MT Newswires

2 days ago

RBC Trims Price Target on Cytokinetics to $80 From $82, Keeps Outperform, Speculative Risk

Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges

GuruFocus.com

2 days ago

Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges

Argus Research

2 days ago

CYTK: Lowering target price to $27.00

MT Newswires

2 days ago

Cytokinetics Q1 Net Loss Widens, Revenue Rises

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Zacks

2 days ago

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

2 days ago

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

Cytokinetics Inc (CYTK) Q1 2025: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

3 days ago

Cytokinetics Inc (CYTK) Q1 2025: Everything You Need To Know Ahead Of Earnings

Why Cytokinetics, Inc. (CYTK) Went Down On Friday

Insider Monkey

6 days ago

Why Cytokinetics, Inc. (CYTK) Went Down On Friday

MT Newswires

6 days ago

Sector Update: Health Care Stocks Climb Late Afternoon

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

Benzinga

6 days ago

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

MT Newswires

6 days ago

Cytokinetics Shares Fall After FDA Extends Review of Heart Disease Treatment

MT Newswires

7 days ago

UBS Adjusts Price Target on Cytokinetics to $41 From $47, Maintains Neutral Rating

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

BioPharma Dive

7 days ago

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire

7 days ago

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Participate in May Investor Conferences

GlobeNewswire

8 days ago

Cytokinetics to Participate in May Investor Conferences

Argus Research

16 days ago

CYTK: Lowering target price to $30.00

Cytokinetics to Announce First Quarter Results on May 6, 2025

GlobeNewswire

16 days ago

Cytokinetics to Announce First Quarter Results on May 6, 2025

Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

TipRanks

17 days ago

Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

MT Newswires

17 days ago

Cytokinetics Insider Sold Shares Worth $769,200, According to a Recent SEC Filing

Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now?

Insider Monkey

21 days ago

Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now?

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

21 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

23 days ago

CYTK: Raising target price to $31.00

BMY Down on Heart Drug Camzyos Failure in Late-Stage Study

Zacks

24 days ago

BMY Down on Heart Drug Camzyos Failure in Late-Stage Study

Bristol Myers stumbles in bid to widen heart drug’s use

BioPharma Dive

24 days ago

Bristol Myers stumbles in bid to widen heart drug’s use

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

Investor's Business Daily

24 days ago

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

The Wall Street Journal

a month ago

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Argus Research

a month ago

CYTK: Lowering target price to $28.00

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Zacks

a month ago

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Investor's Business Daily

a month ago

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

Investopedia

a month ago

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

Argus Research

a month ago

CYTK: Lowering target price to $30.00

MT Newswires

a month ago

Cytokinetics Insider Sold Shares Worth $611,250, According to a Recent SEC Filing

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

a month ago

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy

Insider Monkey

a month ago

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy

Argus Research

a month ago

CYTK: Raising target price to $36.00

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey

a month ago

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

Zacks

a month ago

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

GlobeNewswire

2 months ago

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

2 months ago

Cytokinetics Insider Sold Shares Worth $943,426, According to a Recent SEC Filing

MT Newswires

2 months ago

UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

GlobeNewswire

2 months ago

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

MT Newswires

2 months ago

Cytokinetics Insider Sold Shares Worth $1,080,750, According to a Recent SEC Filing

MT Newswires

2 months ago

Cytokinetics Insider Sold Shares Worth $374,900, According to a Recent SEC Filing

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Simply Wall St.

2 months ago

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Argus Research

2 months ago

CYTK: Lowering target price to $35.00

Cytokinetics to Participate in March Investor Conferences

GlobeNewswire

2 months ago

Cytokinetics to Participate in March Investor Conferences

Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

2 months ago

Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

Zacks

2 months ago

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Cytokinetics Inc Earnings Call

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Cytokinetics to $96 From $98, Maintains Outperform Rating

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses

GuruFocus.com

2 months ago

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Zacks

2 months ago

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Associated Press Finance

2 months ago

Cytokinetics: Q4 Earnings Snapshot

MT Newswires

2 months ago

Cytokinetics Q4 Net Loss Narrows, Revenue Rises

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

2 months ago

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

Cytokinetics Inc (CYTK) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

2 months ago

Cytokinetics Inc (CYTK) Q4 2024: Everything You Need To Know Ahead Of Earnings

Argus Research

2 months ago

CYTK: Raising target price to $37.00

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey

3 months ago

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now

Insider Monkey

3 months ago

Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

3 months ago

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

3 months ago

CYTK: Raising target price to $36.00

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

GlobeNewswire

3 months ago

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

MT Newswires

3 months ago

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Adjusts Price Target to $67 From $70

MT Newswires

3 months ago

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70

Cytokinetics Names Robert E. Landry to Board of Directors

GlobeNewswire

3 months ago

Cytokinetics Names Robert E. Landry to Board of Directors

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

Insider Monkey

3 months ago

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

MT Newswires

3 months ago

Citigroup Initiates Cytokinetics at Buy With $86 Price Target

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

3 months ago

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MT Newswires

3 months ago

B. Riley Adjusts Cytokinetics' Price Target to $88 From $92, Keeps Buy Rating

Argus Research

3 months ago

CYTK: What does Argus have to say about CYTK?

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Zacks

3 months ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

GlobeNewswire

3 months ago

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Zacks

3 months ago

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Argus Research

3 months ago

CYTK: Raising target price to $39.00

What Are Analysts Talking About Cytokinetics (CYTK)?

Insider Monkey

3 months ago

What Are Analysts Talking About Cytokinetics (CYTK)?

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Zacks

4 months ago

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Benzinga

4 months ago

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Argus Research

4 months ago

CYTK: Raising target price to $37.00

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

GlobeNewswire

4 months ago

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

Argus Research

4 months ago

CYTK: Lowering target price to $36.00

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

GlobeNewswire

4 months ago

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

4 months ago

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

4 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Argus Research

5 months ago

CYTK: Raising target price to $51.00

MT Newswires

5 months ago

Cytokinetics Says European Regulator Validated its Application for Cardiomyopathy Drug Candidate

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire

5 months ago

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Why Cytokinetics Stock Was a Nearly 5% Winner Today

Motley Fool

5 months ago

Why Cytokinetics Stock Was a Nearly 5% Winner Today

MT Newswires

5 months ago

Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

GlobeNewswire

5 months ago

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)

Simply Wall St.

5 months ago

Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)

MT Newswires

5 months ago

RBC Raises Price Target on Cytokinetics to $82 From $80, Keeps Outperform, Speculative Risk

Argus Research

5 months ago

CYTK: Lowering target price to $50.00

Argus Research

5 months ago

CYTK: Rating increased to a HOLD

Share on Social Networks: